Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of CardiologyReferences
- Plasma high-density-lipoprotein concentration and development of ischaemic heart disease.Lancet. 1975; 1: 16-19
- Risk factors for myocardial infarction in the Stockholm prospective study.Acta Med Scand. 1979; 206: 351-360
- Incidence of coronary heart disease and lipoprotein cholesterol levels.JAMA. 1986; 256: 2385-2387
- Plasma triglyceride level in a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level.J Cardiovasc Risk. 1996; 3: 213-219
- Low-density lipoprotein subclass patterns and risk of myocardial infarction.JAMA. 1988; 260: 1917-1921
- Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles.J Clin Invest. 1993; 92: 141-146
- Relation of high TG-low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease. An 8-year follow-up in the Copenhagen Male Study.Arterioscler Thromb Vasc Biol. 1997; : 1114-1120
- Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction.Circulation. 1997; 96: 2520-2525
- Evaluation of octreotide to assess insulin-mediated glucose disposal by the insulin suppression test.Diabetologia. 1994; 37: 843-845
- Comparison of impedance to insulin-mediated glucose uptake in normal and diabetic subjects.J Clin Invest. 1970; 49: 2151-2160
- Assessment of insulin resistance with the insulin suppression test and the euglycemic clamp.Diabetes. 1981; 30: 387-392
- Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy, nondiabetic volunteers.Diabetes Care. 2000; 23: 171-175
- Immunoassay of insulin with insulin-antibody precipitate.Biochem J. 1963; 88: 137-146
- Relationship to insulin resistance of the Adult Treatment Panel III diagnostic criteria for identification of the metabolic syndrome.Diabetes. 2004; 53: 1195-1200
- Reappraisal of the role of insulin in hypertriglyceridemia.Am J Med. 1974; 57: 551-560
- Evidence for an independent relationship between insulin resistance and fasting plasma HDL-cholesterol, triglyceride and insulin concentrations.J Int Med. 1992; 231: 25-30
- Low-density-lipoprotein subclasses and response to a low-fat diet in healthy men.Am J Clin Nutr. 1995; 62: 478S-487S
- Reduced LDL particle size in children consuming a very-low-fat diet is related to parental LDL-subclass patterns.Am J Clin Nutr. 2000; 71: 1611-1616
- LDL subclass patterns and lipoprotein response to a low-fat, high-carbohydrate diet in women.Arterioscler Thromb Vasc Biol. 1997; 17: 707-714
- Epidemiology Study Design and Data Analysis. Chapman & Hall/CRC Press, Boca Raton, Florida1999
- Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).JAMA. 2002; 285: 2846-2897
- How good a marker is insulin level for insulin resistance?.Am J Epidemiol. 1992; 137: 959-965
- Role of insulin resistance in human disease.Diabetes. 1988; 37: 1595-1607
- The insulin resistance syndrome.Curr Atheroscler Rep. 2003; 5: 364-371
- The plasma parameter log (TG/HDL-C) as an atherogenic index.Clin Biochem. 2001; 34: 583-588
- Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease.J Clin Endocrinol Metab. 1998; 83: 2773-2776
- Insulin resistance as a predictor of age-related diseases.J Clin Endocrinol Metab. 2001; 86: 3574-3578
Article info
Publication history
Footnotes
Dr. Krauss was supported by a grant from the National Dairy Council, Rosemont, Illinois. Drs. Krauss, Waters, Saad, and Simon were supported by Grant U01-HL6975, Drs. McLaughlin, Reaven, Abbasi, and Ms. Lamendola were supported by Grant RR000070, and Dr. McLaughlin was supported by Grant RR16071-01 from the National Institutes of Health, Bethesda, Maryland. The funding sources had no role in the design, conduct, or manuscript preparation for this study.